(VIANEWS) – Southwest Gas Corporation (SWX), Halozyme Therapeutics (HALO), Astec Industries (ASTE) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Southwest Gas Corporation (SWX)

86.2% sales growth and 10.15% return on equity

Southwest Gas Holdings, Inc., through its subsidiaries, purchases, distributes, and transports natural gas in Arizona, Nevada, and California.

Southwest Gas Corporation’s sales growth this year is expected to be 5.1% and 12.6% for next year.

Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 3.35B for the twelve trailing months.

Volume

Today’s last reported volume for Southwest Gas Corporation is 415041 which is 9.22% below its average volume of 457220.

Southwest Gas Corporation’s sales growth is a negative 0% for the current quarter and 86.2% for the next. The company’s growth estimates for the present quarter and the next is a negative 35.3% and negative -59.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.15%.

Volatility

Southwest Gas Corporation’s last day, last week, and last month’s current volatility was 0.86%, 0.80%, and 1.20%, respectively.

Southwest Gas Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.20% (day), 1.91% (last week), and 2.30% (last month), respectively.

Southwest Gas Corporation’s Stock Yearly Top and Bottom Value

Southwest Gas Corporation’s stock is valued at $72.92 at 01:22 EST, below its 52-week high of $75.00 and way higher than its 52-week low of $57.00.

Southwest Gas Corporation’s Moving Average

Southwest Gas Corporation’s value is higher than its 50-day moving average of $67.80 and higher than its 200-day moving average of $66.89.

2. Halozyme Therapeutics (HALO)

57.3% sales growth and 259.61% return on equity

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.

Halozyme Therapeutics’s sales growth this year is expected to be 51.2% and 42.4% for next year.

Year-on-year quarterly revenue growth grew by 251.1%, now sitting on 331.26M for the twelve trailing months.

Volume

Today’s last reported volume for Halozyme Therapeutics is 544309 which is 38.01% below its average volume of 878168.

Halozyme Therapeutics’s sales growth for the next quarter is 57.3%. The company’s growth estimates for the current quarter and the next is 110.5% and 52%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 259.61%.

Volatility

Halozyme Therapeutics’s last day, last week, and last month’s current volatility was 0.40%, 0.98%, and 1.32%, respectively.

Halozyme Therapeutics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.94% (day), 2.65% (last week), and 2.97% (last month), respectively.

Halozyme Therapeutics’s Stock Yearly Top and Bottom Value

Halozyme Therapeutics’s stock is valued at $40.14 at 01:22 EST, way under its 52-week high of $56.40 and way above its 52-week low of $25.17.

Halozyme Therapeutics’s Moving Average

Halozyme Therapeutics’s worth is under its 50-day moving average of $43.45 and way under its 200-day moving average of $44.71.

3. Astec Industries (ASTE)

22.5% sales growth and 5.59% return on equity

Astec Industries, Inc. designs, engineers, manufactures, and markets equipment and components used primarily in road building and related construction activities in the United States and internationally.

Astec Industries’s sales growth this year is expected to be 12.5% and 10.1% for next year.

Year-on-year quarterly revenue growth declined by 1.5%, now sitting on 1.02B for the twelve trailing months.

Volume

Today’s last reported volume for Astec Industries is 200314 which is 45.01% above its average volume of 138134.

Astec Industries’s sales growth is a negative 0% for the current quarter and 22.5% for the next. The company’s growth estimates for the present quarter and the next is a negative 25.4% and 165%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.59%.

Volatility

Astec Industries’s last day, last week, and last month’s current volatility was 1.53%, 1.34%, and 1.59%, respectively.

Astec Industries’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.61% (day), 3.77% (last week), and 3.18% (last month), respectively.

Astec Industries’s Stock Yearly Top and Bottom Value

Astec Industries’s stock is valued at $59.60 at 01:22 EST, way under its 52-week high of $80.00 and way higher than its 52-week low of $48.28.

Astec Industries’s Moving Average

Astec Industries’s worth is under its 50-day moving average of $60.51 and way under its 200-day moving average of $67.66.

Previous days news about Astec Industries(ASTE)

Recap: astec industries Q2 earnings. According to Benzinga on Wednesday, 4 August, "Shares of Astec Industries (NASDAQ:ASTE) remained unaffected after the company reported Q2 results."

4. Eli Lilly and Company (LLY)

15% sales growth and 118.34% return on equity

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.

Eli Lilly and Company’s sales growth this year is expected to be 10.9% and 2.3% for next year.

Year-on-year quarterly revenue growth grew by 16.1%, now sitting on 25.49B for the twelve trailing months.

Volume

Today’s last reported volume for Eli Lilly and Company is 1900660 which is 42.02% below its average volume of 3278520.

Eli Lilly and Company’s sales growth for the next quarter is 15%. The company’s growth estimates for the ongoing quarter and the next is 1.6% and 22.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 118.34%.

Volatility

Eli Lilly and Company’s last day, last week, and last month’s current volatility was 0.66%, 1.80%, and 1.02%, respectively.

Eli Lilly and Company’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.60% (day), 3.39% (last week), and 2.07% (last month), respectively.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $263.44 at 01:22 EST, below its 52-week high of $270.65 and way higher than its 52-week low of $129.21.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is way higher than its 50-day moving average of $235.55 and way higher than its 200-day moving average of $207.15.

5. Quanex Building Products Corporation (NX)

9.2% sales growth and 15.41% return on equity

Quanex Building Products Corporation, together with its subsidiaries, provides components for the fenestration industry worldwide.

Quanex Building Products Corporation’s sales growth this year is anticipated to be 23.3% and 3.1% for next year.

Year-on-year quarterly revenue growth grew by 44.2%, now sitting on 968M for the twelve trailing months.

Volume

Today’s last reported volume for Quanex Building Products Corporation is 134798 which is 19.36% below its average volume of 167171.

Quanex Building Products Corporation’s sales growth is a negative 0% for the current quarter and 9.2% for the next. The company’s growth estimates for the current quarter and the next is 41.2% and negative -17.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.41%.

Volatility

Quanex Building Products Corporation’s last day, last week, and last month’s current volatility was 1.69%, 1.59%, and 1.43%, respectively.

Quanex Building Products Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.83% (day), 2.84% (last week), and 2.77% (last month), respectively.

Quanex Building Products Corporation’s Stock Yearly Top and Bottom Value

Quanex Building Products Corporation’s stock is valued at $24.69 at 01:22 EST, way under its 52-week high of $29.02 and way above its 52-week low of $14.77.

Quanex Building Products Corporation’s Moving Average

Quanex Building Products Corporation’s value is higher than its 50-day moving average of $24.43 and below its 200-day moving average of $25.59.

6. Xylem (XYL)

8.2% sales growth and 10.51% return on equity

Xylem Inc. engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally.

Xylem’s sales growth this year is expected to be 9.2% and 6% for next year.

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 5.01B for the twelve trailing months.

Volume

Today’s last reported volume for Xylem is 763411 which is 5.41% below its average volume of 807123.

Xylem’s sales growth for the next quarter is 8.2%. The company’s growth estimates for the current quarter and the next is 55% and 12.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.51%.

Volatility

Xylem’s last day, last week, and last month’s current volatility was 1.65%, 0.99%, and 0.95%, respectively.

Xylem’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.43% (day), 2.37% (last week), and 1.76% (last month), respectively.

Xylem’s Stock Yearly Top and Bottom Value

Xylem’s stock is valued at $128.80 at 01:22 EST, above its 52-week high of $125.25.

Xylem’s Moving Average

Xylem’s value is above its 50-day moving average of $119.10 and way higher than its 200-day moving average of $109.66.

LEAVE A REPLY

Please enter your comment!
Please enter your name here